MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marbeuf-Gueye, C.
Right arrow Articles by Garnier-Suillerot, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marbeuf-Gueye, C.
Right arrow Articles by Garnier-Suillerot, A.

Vol. 53, Issue 1, 141-147, January 1998

Kinetics of Anthracycline Efflux from Multidrug Resistance Protein-Expressing Cancer Cells Compared with P-Glycoprotein-Expressing Cancer Cells

C. Marbeuf-Gueye, H. J. Broxterman, F. Dubru, W. Priebe and A. Garnier-Suillerot

Laboratoire de Physicochimie Biomoléculaire et Cellulaire (URA Centre National de la Recherche Scientifique 2056), Université Paris Nord, Bobigny 93017, France (C.M.-G., F.D.), Department of Medical Oncology, Academisch Ziekenhuis Vrije Universiteit, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands (H.J.B.), and The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030 (W.P.)

The multidrug resistance protein (MRP) has been shown to mediate ATP-dependent efflux of anticancer agents of diverse structure, such as daunorubicin (DNR), vincristine and etoposide. Thus, this protein does confer a multidrug resistant phenotype to cancer cells, similar to P-glycoprotein (Pgp). The substrate specificity of both transporter proteins is partly overlapping but is otherwise very distinct; because MRP is a multiple organic anion transporter, it transports certain glutathione conjugates and may be partly dependent on intracellular glutathione levels for the transport of anthracyclines. We have studied the transport kinetics of a series of anthracyclines in MRP and Pgp that overexpress tumor cell lines to obtain information on the substrate specificity of these proteins. The anthracyclines have modifications in the sugar moiety. The mean active efflux coefficient ka, used to characterize the efficiency of the active efflux, was very similar for DNR and one of its 4'-deoxy- derivatives (eso-DNR) for MRP and Pgp [10-20 × 10-10/sec/(cells/ml)]. The permanently neutral derivatives 3'-deamino-3'-hydroxy-doxorubicin (OH-DOX) and 3'-deamino-3'-hydroxy-daunorubicin (OH-DNR) were effluxed by both proteins but had a lower ka [2 × 10-10 and 6 × 10-10/sec/(cells/ml) (OH-DOX) and 2 × 10-10 and 5 × 10-10/sec/(cells/ml) (OH-DNR)] for MRP and Pgp. Two anthracyclines, the doxorubicin derivative pirarubicin and 2'-bromo-4'-epi-DNR seemed to have a slightly higher ka value for Pgp than for MRP. The apparent Michaelis-Menten constants (Km) and maximal efflux rates (VM) for the active transport were within a narrow range for both transporters, except for OH-DOX and OH-DNR, which had a lower VM in the case of MRP-mediated transport, suggesting a role of the amino group in the interaction with glutathione. Determination of the Hill coefficient (nH) of the MRP-mediated efflux gave most values close to 2, which suggests cooperativity of the transport of anthracyclines as reported before for Pgp. In conclusion, the transport kinetics of anthracyclines by MRP and Pgp are very similar.


Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
F. R. Luo, P. V. Paranjpe, A. Guo, E. Rubin, and P. Sinko
Intestinal Transport of Irinotecan in Caco-2 Cells and MDCK II Cells Overexpressing Efflux Transporters Pgp, cMOAT, and MRP1
Drug Metab. Dispos., July 1, 2002; 30(7): 763 - 770.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Rousselle, M. Smirnova, P. Clair, J.-M. Lefauconnier, A. Chavanieu, B. Calas, J.-M. Scherrmann, and J. Temsamani
Enhanced Delivery of Doxorubicin into the Brain via a Peptide-Vector-Mediated Strategy: Saturation Kinetics and Specificity
J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 124 - 131.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
D. M. van der Kolk, E. G. E. de Vries, W. L. J. van Putten, L. F. Verdonck, G. J. Ossenkoppele, G. E. G. Verhoef, and E. Vellenga
P-glycoprotein and Multidrug Resistance Protein Activities in Relation to Treatment Outcome in Acute Myeloid Leukemia
Clin. Cancer Res., August 1, 2000; 6(8): 3205 - 3214.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
V. Vukovic, T. Nicklee, and D. W. Hedley
Microregional Heterogeneity of Non-Protein Thiols in Cervical Carcinomas Assessed by Combined Use of HPLC and Fluorescence Image Analysis
Clin. Cancer Res., May 1, 2000; 6(5): 1826 - 1832.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. L. O'Brien, B. Vulevic, S. Freer, J. Boyd, H. Shen, and K. D. Tew
Glutathione Peptidomimetic Drug Modulator of Multidrug Resistance-Associated Protein
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1348 - 1355.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics